5eak
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
<StructureSection load='5eak' size='340' side='right' caption='[[5eak]], [[Resolution|resolution]] 2.80Å' scene=''> | <StructureSection load='5eak' size='340' side='right' caption='[[5eak]], [[Resolution|resolution]] 2.80Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[5eak]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5EAK OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5EAK FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[5eak]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5EAK OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5EAK FirstGlance]. <br> |
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=24R:N-[(1S,2R)-2-AMINOCYCLOHEXYL]-4-[6-(1-METHYL-1H-PYRAZOL-4-YL)PYRAZOLO[1,5-A]PYRIMIDIN-3-YL]THIOPHENE-2-CARBOXAMIDE'>24R</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=24R:N-[(1S,2R)-2-AMINOCYCLOHEXYL]-4-[6-(1-METHYL-1H-PYRAZOL-4-YL)PYRAZOLO[1,5-A]PYRIMIDIN-3-YL]THIOPHENE-2-CARBOXAMIDE'>24R</scene></td></tr> | ||
| + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">MARK2, EMK1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5eak FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5eak OCA], [http://pdbe.org/5eak PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5eak RCSB], [http://www.ebi.ac.uk/pdbsum/5eak PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5eak ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5eak FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5eak OCA], [http://pdbe.org/5eak PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5eak RCSB], [http://www.ebi.ac.uk/pdbsum/5eak PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5eak ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| Line 20: | Line 21: | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
| + | [[Category: Human]] | ||
[[Category: Su, H P]] | [[Category: Su, H P]] | ||
[[Category: Catalytic domain]] | [[Category: Catalytic domain]] | ||
Revision as of 09:54, 22 November 2017
Optimization of Microtubule Affinity Regulating Kinase (MARK) Inhibitors with Improved Physical Properties
| |||||||||||
